688193.SHG Shanghai Rendu Biotechnology Co. Ltd. A
- Market cap
- CNY 1.68B
- P/E
- 73.5x
- P/B
- 1.86x
- ROE
- 2.2%
- Dividend yield
- 0.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688193.SHG undervalued?
Graham number688193.SHG trades 146.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Rendu Biotechnology Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Rendu Biotechnology Co. Ltd. A yet.
Shanghai Rendu Biotechnology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of molecular diagnostic reagents products and supporting equipment in China and internationally. Its products are used in various therapeutic areas, including reproductive tract, respiratory tract, enterovirus infections, and bloodborne infectious diseases, as well as tumor auxiliary diagnosis. The company was founded in 2007 and is based in Shanghai, China.
Full company profileShanghai Rendu Biotechnology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Rendu Biotechnology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 99.2M | 250M | 292M | 304M | 164M | 177M | 162M | 159M |
| Gross Profit | 88.1M | 190M | 218M | 199M | 134M | 141M | 126M | 125M |
| Operating Income | 3.40M | 68.7M | 70.0M | 18.9M | -8.32M | -12.1M | -14.3M | 8.75M |
| EBITDA | 7.63M | 76.1M | 82.9M | 41.7M | 21.0M | 2.19M | 26.8M | 20.9M |
| Net Income | 3.74M | 61.4M | 64.6M | 23.3M | 8.26M | -7.81M | 10.1M | 19.2M |
| EPS | 0.12 | 2.05 | 2.15 | 0.58 | 0.21 | -0.20 | 0.25 | 0.48 |
| Balance Sheet | ||||||||
| Total Assets | 187M | 311M | 379M | 1.09B | 1.05B | 994M | 990M | 948M |
| Total Liabilities | 36.4M | 95.8M | 90.9M | 127M | 92.0M | 82.5M | 76.3M | 64.4M |
| Shareholders' Equity | 151M | 215M | 288M | 961M | 963M | 912M | 914M | 884M |
| Cash & Short-term Investments | 42.2M | 172M | 198M | 299M | 610M | 262M | 97.4M | 137M |
| Cash Flow | ||||||||
| Operating Cash Flow | 13.7M | 92.6M | 54.4M | -4.09M | 17.2M | 24.4M | 22.4M | - |
| Capital Expenditure | 54.8M | 15.5M | 26.5M | 21.2M | 20.4M | 10.5M | 7.07M | 0.00 |
| Free Cash Flow | -41.2M | 77.1M | 28.0M | -25.3M | -3.20M | 13.9M | 15.3M | -4.11M |
| Ratios | ||||||||
| ROE | 2.5% | 28.5% | 22.5% | 2.4% | 0.9% | -0.9% | 1.1% | 2.2% |
| ROA | 2.0% | 19.7% | 17.1% | 2.1% | 0.8% | -0.8% | 1.0% | 2.0% |
| Net Profit Margin | 3.8% | 24.6% | 22.1% | 7.7% | 5.0% | -4.4% | 6.2% | 12.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Rendu Biotechnology Co. Ltd. A dividends
- Dividend yield
- 0.58%
- Forward dividend
- 1.15 CNY
- Payout ratio
- 96.0%
- Ex-dividend date
- Jun 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 9.69M | 0.24 | 96.0% |
| 2024 | CNY 11.7M | 0.29 | - |
| 2023 | CNY 5.00M | 0.13 | 60.5% |
| 2022 | - | - | - |
| 2021 | CNY 53.2K | 0.00 | 0.1% |
| 2020 | CNY 138K | 0.00 | 0.2% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Rendu Biotechnology Co. Ltd. A
- Insiders 51.67%
- Institutions 4.30%
- Public & others 44.04%
- Shares outstanding 40.1M
- Free float 23.1M
Shanghai Rendu Biotechnology Co. Ltd. A company profile
- Company name
- Shanghai Rendu Biotechnology Co. Ltd. A
- Ticker
- 688193.SHG
- ISIN
- CNE1000059K5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 239
- Fiscal year end
- December
- Address
- Building 15, Shanghai, China, 201201
- Phone
- 86 21 5072 0200
- Website
- rdbio.com
About Shanghai Rendu Biotechnology Co. Ltd. A
Shanghai Rendu Biotechnology Co., Ltd. engages in the research, development, production, and sales of molecular diagnostic reagents products and supporting equipment in China and internationally. Its products are used in various therapeutic areas, including reproductive tract, respiratory tract, enterovirus infections, and bloodborne infectious diseases, as well as tumor auxiliary diagnosis. The company was founded in 2007 and is based in Shanghai, China.
Shanghai Rendu Biotechnology Co. Ltd. A management
7- Mr. Jinliang JuChairman of the Board & Chief Scientist · born 1966
- Ms. Minghui YuGM & Director · born 1983
- Mr. Tingjiang CaiAccounting Officer, Accounting Supervisor, CFO & Secretary · born 1974
- Ms. Ruohua CaoDeputy GM & Director · born 1966
- Ms. Zhenling CuiSenior Director of R&D · born 1978
- Mr. Hao JinDeputy Director of Instrument R&D Department · born 1990
- Ms. Chang E ZhangRegistration Director & Director of Manufacturing Center · born 1980